A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Alkermes plc
- 31 Aug 2018 Biomarkers information updated
- 02 Apr 2018 Planned number of patients changed from 325 to 450.
- 02 Apr 2018 Planned End Date changed from 1 Nov 2019 to 1 Aug 2021.